The therapeutic effects of a progesterone-releasing intravaginal device (PRID) with attached estradiol capsule on ovarian quiescence and cystic ovarian disease in postpartum dairy cows

The objective of this study was to evaluate the effects of a progesterone-releasing intravaginal device (PRID) containing an estradiol benzoate capsule on ovarian dysfunction, including ovarian quiescence, follicular cyst (FC) and luteal cyst or cystic corpus luteum (LC/CCL), in postpartum dairy cows. These ovarian dysfunctions were examined by palpation per rectum relative to plasma progesterone status. The results of clinical examination and hormone assay determined ovarian quiescence in 13 cows, FC in 15 cows and LC/CCL in 7 cows. These cows were treated with PRID for 12 d and then clinical examination was performed. After PRID removal, the proportion of cows exhibiting estrous signs within 7 d and confirmed formation of CL within 7-14 d (markedly effective) were 69.2 % (n = 9) for ovarian quiescence, 46.7 % (n = 7) for FC, and 28.6 % (2 cows) for LC/CCL. Two cows (15.4%) in ovarian quiescence, 5 cows (33.3%) with FC and 4 cows (57.1%) with LC/CCL did not exhibit estrous signs but were recognized as having formed CL within 12-16 d after removal of PRID (effective). These results suggest that treatments of PRID with estradiol benzoate for 12 d have therapeutic efficacy on ovarian dysfunction including ovarian quiescence, FC and LC/CCL in postpartum dairy cows.